Dr. Leon (Hongliang) Zong has been the Vice President of Production, Research & Development and General Manager of Shanghai EXUMA Biotech since December 2018. He was previously the Vice President of Production, Research & Development for PerHum Therapeutics from June 2017 to November 2018 where he was responsible for CAR-T manufacturing related production, warehouse management, purchasing, cell process R&D, CRO collaboration and clinical trial-related molecular diagnostic technologies. He was the Chief Scientific Officer of Tofflon Healthcare from April 2016 to June 2017, where he led the R&D team to development and preclinical studies for the universal CAR-T product targeting hematologic malignancies and solid tumors. From 2010 to 2016, Dr. Zong was a research associate at Weill Cornell Medical College, where he endeavored to develop targeted therapies including multi-stage nanoparticles, small inhibitors for aberrantly activated signaling pathways and molecular chaperones, and universal CAR-T for AML stem cells. Dr. Zong earned his B.M. in Preventative Medicine and Ph.D. in Biochemistry and Molecular Biology from Shanghai Medical College of Fudan University.